8-K filed Nov 6, 2026 at 07:05 ET
Treace Medical Concepts reported Q3 2026 revenue of $48.3M, down 4% YoY from $50.2M, but net loss narrowed 23% to $(12.6)M and Adjusted EBITDA turned positive at $0.3M. The company narrowed its full-year 2026 revenue guidance to $206M-$210M (from $204M-$212M) and improved its Adjusted EBITDA loss guidance to $1.0M-$2.0M (from $3.0M-$5.0M). Revenue decline persists due to product mix shift toward lower-priced minimally invasive products, though case volume grew double digits.